PTC Therapeutics Inc Asset Resilience Ratio

Latest as of March 2026: 36.89%

PTC Therapeutics Inc asset resilience ratio. PTC Therapeutics Inc (PTCT) has an Asset Resilience Ratio of 36.89% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of PTC Therapeutics Inc for a breakdown of total debt and financial obligations.

Liquid Assets

$1.06 Billion
Cash + Short-term Investments

Total Assets

$2.87 Billion
All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio of PTC Therapeutics Inc (2004–2025)

Asset resilience ratio of PTC Therapeutics Inc from 2004 to 2025. This chart shows how PTC Therapeutics Inc's Asset Resilience Ratio has changed over time. See PTCT free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.

Liquid Assets Composition Over Time

This chart breaks down PTC Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see PTCT asset base.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $1.06 Billion 36.89%
Total Liquid Assets $1.06 Billion 36.89%

Asset Resilience Insights

  • Very High Liquidity: PTC Therapeutics Inc maintains exceptional liquid asset reserves at 36.89% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

PTC Therapeutics Inc Industry Peers by Asset Resilience Ratio

Compare PTC Therapeutics Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
HLB Co. Ltd
KQ:028300
Biotechnology 3.29%
Tubize-Fin
BR:TUB
Biotechnology 2.50%
Shanghai Medicilon Inc
SHG:688202
Biotechnology 6.69%
Blue Jet Healthcare Limited
NSE:BLUEJET
Biotechnology 13.81%
Hangzhou Biotest Biotech Co Ltd
SHG:688767
Biotechnology 0.56%
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
Biotechnology 79.76%
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
Biotechnology 5.52%

PTC Therapeutics Inc Asset Resilience Ratio by Year (2004–2025)

PTC Therapeutics Inc asset resilience ratio by year from 2004 to 2025. The table below shows the annual Asset Resilience Ratio data for PTC Therapeutics Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 33.00% $960.72 Million $2.91 Billion +11.89pp
2024-12-31 21.11% $359.99 Million $1.71 Billion +6.20pp
2023-12-31 14.91% $282.74 Million $1.90 Billion +7.24pp
2022-12-31 7.67% $130.87 Million $1.71 Billion -22.44pp
2021-12-31 30.12% $583.66 Million $1.94 Billion -10.41pp
2020-12-31 40.52% $894.84 Million $2.21 Billion +15.98pp
2019-12-31 24.54% $398.54 Million $1.62 Billion +19.35pp
2018-12-31 5.19% $58.09 Million $1.12 Billion -15.10pp
2017-12-31 20.29% $79.45 Million $391.65 Million -44.07pp
2016-12-31 64.36% $173.34 Million $269.35 Million -11.97pp
2015-12-31 76.32% $280.90 Million $368.04 Million -3.35pp
2014-12-31 79.68% $265.49 Million $333.22 Million -3.97pp
2013-12-31 83.64% $127.05 Million $151.90 Million +22.52pp
2005-12-31 61.12% $26.88 Million $43.97 Million -6.14pp
2004-12-31 67.26% $26.21 Million $38.97 Million --
pp = percentage points

About PTC Therapeutics Inc

NASDAQ:PTCT USA Biotechnology
Market Cap
$4.97 Billion
Market Cap Rank
#3478 Global
#1244 in USA
Share Price
$59.97
Change (1 day)
-6.97%
52-Week Range
$59.24 - $89.55
All Time High
$89.55
About

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervo… Read more